Sökning: "phase 1 trials"
Visar resultat 11 - 15 av 74 avhandlingar innehållade orden phase 1 trials.
11. A Path for Improving Stroke Recovery. Effects of MEK-ERK1/2 Inhibition
Sammanfattning : The present thesis aimed to shed more light on the notion of acute inhibition of extracellular-signal regulated kinase (ERK)1/2 pathway as a treatment to improve stroke recovery. Stroke is a major cause of death and long-term disability worldwide, classified as ischemic or hemorrhagic. LÄS MER
12. Biomarkers for eligibility and surrogate endpoints in heart failure trials
Sammanfattning : Background: In heart failure (HF) with reduced ejection fraction (HFrEF), randomized controlled trials have provided effective treatments, but prognosis still remains poor. HF with mid-range EF (HFmrEF) has no evidencebased therapy and represents a newly characterized and relevant population for future trials. LÄS MER
13. Characteristics of GADA in Type 1 Diabetes following Immunomodulation with GAD65
Sammanfattning : Type 1 diabetes (T1D) is a serious autoimmune disease which increases worldwide and affects children at a young age, but there still is no cure available. Clinical intervention trials in recent onset T1D patients are therefore very important, since even a modest preservation of β-cell function has proven to reduce end-organ complications. LÄS MER
14. Athletic Sprint Start Biomechanics : Investigations into the relationships between three dimensional starting technique, first step width and performance
Sammanfattning : The block and early acceleration phase plays a very important role in the overall outcome of athletic sprint events. During this part of the race it is commonly observed that sprinters use a lower-body technique that involves the swing leg crossing medially in front of the athlete followed by wide steps. LÄS MER
15. Insulin-like growth factor 1 receptor, novel functions and future possibilities
Sammanfattning : Insulin like growth factor-1 receptor (IGF-1R) has been shown to be important for cancer cell growth and survival, and is often overexpressed in malignant and premalignant tissues. Ligand binding to IGF-1R induces transphosphorylation and activation of the receptor, leading to subsequent activation of the phosphatidyl inositol-3 kinase (PI3K), the mitogen-activated protein kinase (MAPK) and the 14-3-3 pathways. LÄS MER